Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | PHASE1 | COMPLETED | 111 | — | — | Mar 1, 2008 | Feb 1, 2013 | Dec 17, 2020 | 28 | United States, Australia +9 |
| Arm | Type | Description |
|---|---|---|
| HCD122 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| HCD122 | DRUG | - |
Inclusion criteria: Patients may be included in the study if they meet all of the following criteria: * Patients must have confirmed diagnosis of HL or NHL (follicular, marginal zone / MALT, diffuse large B-cell, or mantle cell) per REAL/WHO classification * Patients must have progressed after at ...